Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1590P - Treatment outcomes and antibody immunity to SARS-CoV-2 in patients with hematological malignancies


16 Sep 2021


ePoster Display


Clinical Research;  COVID-19 and Cancer

Tumour Site

Haematological Malignancies


Kristina Zakurdaeva


Annals of Oncology (2021) 32 (suppl_5): S1129-S1163. 10.1016/annonc/annonc713


K. Zakurdaeva1, O.A. Gavrilina2, A.N. Vasileva2, S.K. Dubov3, V.S. Dubov3, V.I. Vorobyev4, L.S. Butaev4, L.V. Gavrilova5, I.Y. Toropova6, M. Popova7, A. Siniaev7, K. Kaplanov8, A.A. Petrenko8, O.I. Ochirova9, E.Y. Chelysheva10, Y.V. Sveshnikova11, V. Shuvaev12, M.E. Grishunina13, Y.A. Chabaeva14, V.G. Savchenko2

Author affiliations

  • 1 Na, RakFond, 115563 - Moscow/RU
  • 2 Hematology, National Research Center for Hematology, 125167 - Moscow/RU
  • 3 Hematology, Regional Clinical Hospital #2, Vladivostok/RU
  • 4 Bone Marrow Transplant, S.P. Botkin City Clinical Hospital, Moscow/RU
  • 5 Hematology, Republican Clinical Hospital #4, Saransk/RU
  • 6 Hematology, Regional Clinical Hospital, Yaroslavl/RU
  • 7 Research Institute, Pavlov University, 194022 - Saint-Petersburg/RU
  • 8 Hematology, S.P. Botkin City Clinical Hospital, Moscow/RU
  • 9 Hematology, N.A. Semashko Republican Clinical Hospital, Ulan-Ude/RU
  • 10 Myeloproliferation, National Research Center for Hematology, 125167 - Moscow/RU
  • 11 Hematology, Regional Clinical Hospital, Ekaterinburg/RU
  • 12 Hematology, City Clinical Hospital n.a. V.V. Veresaev Moscow Department of Healthcare, Moscow/RU
  • 13 Hematology, N.A. Semashko Regional Clinical Hospital, Nizhniy Novgorod/RU
  • 14 Biostatistics, National Research Center for Hematology, 125167 - Moscow/RU


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1590P


Since SARS-CoV-2 infection heavily affects vulnerable populations including those with immune suppression, it is of special value to study clinical course, treatment outcomes, and immunity in patients (pts) with hematological (hem) malignancies.


CHRONOS19 is an ongoing observational study in adult pts (≥18 years) with hem diseases (malignant or non-malignant) and COVID-19 in Russia. This web-based registry collected de-identified data from 15 centers all over the country at 30, 90, and 180 days after lab-confirmed or suspected (based on CT and/or clinical symptoms) COVID-19 diagnosis. The primary endpoint was 30-day all-cause mortality.


As of data cut-off on April 14, 2021, 626 pts were enrolled in the study; 562 were eligible for primary endpoint assessment, n (%): M/F 271 (48%) / 291 (52%), median age 56 [18-90] years, malignant disease in 516 (92%) pts, among them induction phase / relapse or refractory / remission / NA in 180 (35%) / 120 (23%) / 187 (36%) / 29 (6%) pts. Thirty-day all-cause mortality in pts with hem malignancies was 19%; 83% of deaths were due to COVID-19 complications. No increase of hem disease relapse rate after COVID-19 was observed at Day 90 or Day 180, although 180-day data was still not mature at the time of analysis. IgG to SARS-CoV-2 was detected in 84% of pts with hem malignancies (167/199). The highest rate of detected antibody immunity was found in pts with chronic myeloproliferative neoplasms (100%; 13/13), HL (100%; 12/12), and multiple myeloma (97%; 34/35), the lowest – in pts with CLL (62%; 8/13) and NHL (60%; 6/10 and 56%; 10/18 for low-grade and high-grade lymphoma, respectively). igG detection rate in CD20+ lymphoma (60%) was significantly lower than in HL or T-cell lymphoma (p=0.004). Pts with ECOG 0-2 throughout the disease had a high rate of antibody immunity (90%; 104/116) vs. those with ECOG 3-4 at the time of COVID-19 diagnosis (77.5%; 31/40) or with worsening of ECOG to 3-4 during the disease (78%; 36/46). Five cases of SARS-CoV-2 re-infection were described.


Pts with hem malignancies and COVID-19 have higher mortality than the general population. Low post-disease antibody immunity to SARS-CoV-2 and cases of re-infection may justify vaccination of these pts and warrant further research.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

National Research Center for Hematology.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.